As a result, novel CYP11A1-derived vitamin D3 hydroxyderivative, including 20(OH) vitamin D3 and 20,23(OH)2 vitamin D3, and lumisterol hydroxymetabolites can inhibit COVID-19 via both independent and nuclear receptor-dependent mechanisms, making them excellent candidates for antiviral drug research as well as the informed use of their precursors as nutrients or supplements in the prevention and attenuation of COVID-19 disease20,21. Here, CYP11A1 is linked to COVID-19.